0.00Open0.00Pre Close0 Volume0 Open Interest6.00Strike Price0.00Turnover0.00%IV-23.97%PremiumDec 20, 2024Expiry Date1.16Intrinsic Value100Multiplier25DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.67Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Candel Therapeutics Stock Discussion
5.30+
Now Let's Get That 10.+ Back!
Let's Get 5.+
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma
Candel Therapeutics announced preclinical results for CAN-3110 in melanoma models, showing potential expansion beyond high-grade glioma treatment. CAN-3110, a first-in-class HSV-1 oncolytic viral immunotherapy, demonstrated potent antitumor activity in both in vitro human cel...
No comment yet